My watch list  

Farnesyltransferase inhibitor

The farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras protein, which is commonly abnormally active in cancer.

Additional recommended knowledge



Studies have suggested that interference with certain post-translational modification processes seem to have quite a high selectivity for targeting cells displaying tumour phenotypes although the reason for this is a matter of controversy (as will be explained below).

After translation, RAS goes through four steps of modification: isoprenylation, proteolysis, methylation and palmitoylation. Isoprenylation involves the enzyme farnesyltransferase (FTase) transferring a farnesyl group from farnesyl pyrophosphate (FPP) to the pre-RAS protein. Also, a related enzyme geranylgeranyltransferase I (GGTase I) has the ability to transfer a geranylgeranyl group to K and N-RAS (the implications of this are discussed below). Farnesyl is necessary to attach RAS to the cell membrane. Without attachment to the cell membrane, RAS is not able to transfer signals from membrane receptors (Reuter et al., 2000).

Development of FTIs

After a program of high-throughput screening of a class of drugs targeting the first step, the farnesyltransferase inhibitors (FTIs) were developed (Reuter et al., 2000). A number of molecules were found to have FTI activity. Some earlier compounds were found to have major side effects, and their development was discontinued. The others have entered clinical trials for different cancers. SCH66336 (Lonafarnib) was the first to do so, followed by R115777 (Zarnestra, Tipifarnib) (Caponigro et al., 2003).

Unfortunately, the predicted “early potential [of FTIs] has not been realised” (Downward J, 2003). The anti-tumour properties of FTIs were attributed to their action on RAS processing; however this assumption has now been questioned. Of the three members (H, N and K) of the RAS family, K-RAS is the form found most often mutated in cancer. As noted above, as well as modification by FFTase an alternative route to creation of biologically active RAS is through GGTase modification. When FFTase is blocked by FFTase inhibitors this pathway comes in to operation – both K and N-RAS are able to be activated through this mechanism. In recognition of this a joint administration of FTIs and GTIs was tried, however this resulted in high toxicity. It is in fact thought that the lack of FTI toxicity may be due to a failure to fully inhibit RAS: FTIs actually target normal cells but alternative pathway allow these cells to surive (Downward J, 2003).

Explaining success

So how to explain the preclinical successes showing that many N- or K-RAS transformed cell lines (and even tumor cell lines that do not harbor RAS mutations) are sensitive to FTase inhibitors? It has been suggested that this is due to inhibition of farnesylation of a number of other proteins (Reuter et al., 2000). Therefore it is hoped that FTIs, whilst not RAS specific, still have potential for cancer therapy.

Products in Development


Investigation of FTIs for alternative uses

FTIs and protozoan parasites

FTIs can also be used to inhibit farnesylation in parasites such as Trypanosoma brucei (African sleeping sickness) and Plasmodium falciparum (malaria). Interestingly, these parasites seem to be more vulnerable to inhibition of Farnesyltransferase than humans, even though the drugs tested selectively target human FTase. In some cases the reason for this may be the parasites lack Geranylgeranyltransferase I. This vulnerability may pave the way for the development of selective, low toxicity, FTI based anti-parasitic drugs 'piggybacking' on the development of FTIs for cancer research.

Use with Progeria

Recently studies have been published indicating that farnesyltransferase inhibitors can act to reverse instability of nuclear structure due to the genetic mutation of the LMNA gene. It is being tested as a potential drug treatment in children suffering from Hutchinson-Gilford Progeria Syndrome.


  • Caponigro F, Casale M, Bryce J. (2003). "Farnesyl transferase inhibitors in clinical development". Expert Opin Investig Drugs. 12:943-54
  • Downward J. (2003). "Targeting the RAS Signalling Pathway in Cancer Therapy". Nat Rev Cancer, 3:11-22
  • Reuter WM, Morgan MA, Bergmann L. (2000). "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?"
  • Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma - H. Lee Moffitt Cancer Center & Research Institute
  • (2006)"The latest exciting news: FTI's - a potential drug treatment for children with Progeria."
  • Eastman, Richard T., Buckner, Frederick S., et al., (2006) Fighting parasitic disease by Blocking Protein Farnesylation, Journal of Lipid Research, 47, 233-240.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Farnesyltransferase_inhibitor". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE